🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 5 of 151

  1. A Phase I/II open label study to assess safety and preliminary evidence of a therapeutic effect of Azeliragon combined with conventional concurrent radiation and temozolomide in patients with newly diagnosed glioblastoma.

    Lacuna Pharma Pty Ltd

    Glioblastoma

    phase 2 other active

    1 trial

  2. A Phase II Multicenter, Open-Label Study to evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Pediatric Patients with Duchenne Muscular Dystrophy (SHIELD DMD)

    Hoffmann-La Roche

    Duchenne Muscular Dystrophy (DMD)

    phase 2 other active

    1 trial

  3. A Phase II, 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in patients with major depressive disorder

    Boehringer Ingelheim

    Major depressive disorder

    phase 2 other active

    1 trial

  4. A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma

    Hoffmann-La Roche

    Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

    phase 2 other active

    1 trial

  5. A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Hoffmann-La Roche

    Previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)

    phase 2 other active

    1 trial

  6. A Phase II, Single-Arm, Open-Label Study Evaluating the Safety and Pharmacokinetics of the Intravenous Fixed‑Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants with Locally Advanced, Recurrent or Metastatic Solid Tumors

    Hoffmann-La Roche

    Solid Tumors

    phase 2 other active

    1 trial

  7. A Phase II, multi-site, open-label, dose-titration trial to investigate the safety, tolerability, pharmacokinetics, and efficacy of Lu AG13909 in adults with Cushing’s disease

    H. Lundbeck A/S

    Cushing's Disease

    phase 2 other active

    1 trial

  8. A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis

    Hoffmann-La Roche

    Relapsing Multiple Sclerosis

    phase 2 other active

    1 trial

  9. A Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding, Adaptive Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Narcolepsy without Cataplexy (NT2)

    Takeda

    Narcolepsy without Cataplexy (NT2)

    phase 2 other active

    1 trial

  10. A Randomized, Open-Label, Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

    Hoffmann-La Roche

    Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

    phase 2 other active

    1 trial

  11. A clinical study of sacituzumab tirumotecan (sac-TMT) in people with bladder cancer (MK-2870-027)

    Merck Sharp and Dohme

    Intermediate-risk Non-muscle Invasive Bladder Cancer

    phase 2 other active

    1 trial

  12. A clinical study to evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination with Daratumumab SC (Tal-D) and Teclistamab SC in Combination with Daratumumab SC (Tec-D) Following Induction with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants with Standard-risk Newly Diagnosed Multiple

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 2 other active

    1 trial

  13. A double-blind, randomized, placebo-controlled, dose-finding phase II study to assess the efficacy and safety of pasireotide s.c. in patients with Post-Bariatric Hypoglycaemia

    Recordati Ireland

    Post-Bariatric Hypoglycaemia

    phase 2 other active

    1 trial

  14. A parallel-group treatment, Phase 2a, multicenter, randomized, double-blind, placebo-controlled umbrella study to evaluate the efficacy and safety of frexalimab, brivekimig and rilzabrutinib in participants aged 16 to 75 years with primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD)

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 2 other active

    1 trial

  15. A phase 2 trial assessing Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis – MODIF-MS

    Pari Pharma GmbH

    Multiple sclerosis

    phase 2 other active

    1 trial

  16. A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of S-337395 in symptomatic nonhospitalized adults with respiratory syncytial virus who are at high risk of progression to severe disease

    Shionogi B.V.

    Respiratory Syncytial Virus

    phase 2 other active

    1 trial

  17. A phase I study evaluating safety and efficacy of Hepatic Intra- Arterial administration of ipilimumab in combination with Intra- venous nivolumab for advanced Hepatocellular carcinoma (HIPANIV)

    The George Institute

    Advanced hepatocellular carcinoma

    phase 2 other active

    1 trial

  18. A phase II trial aiming to investigate the safety and clinical activity of belantamab mafodotin in adult patients with primary immune thrombocytopenia previously treated with a thrombopoietin receptor agonist and/or rituximab after corticosteroid first-line therapy - BONSAI

    Wuhan Createrna Science and Technology Co., Ltd

    Primary Immune Thrombocytopenia

    phase 2 other active

    1 trial

  19. A phase II, monocentric, single arm trial evaluating the efficacy and safety of Pembrolizumab in combination with Lenvatinib in metastatic Uveal MElanoma patients

    The George Institute

    Metastatic uveal melanoma

    phase 2 other active

    1 trial

  20. A prospective, multi-centre study (B-Sure) to evaluate long-term durability of treatment response in chronic hepatitis B participants with and without nucleos(t)ide therapy who have participated in a previous bepirovirsen treatment study.

    GlaxoSmithKline

    Chronic Hepatitis B

    phase 2 other active

    1 trial

  21. A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa

    Sanofi-aventis Healthcare Pty Ltd

    Hidradenitis suppurativa

    phase 2 other active

    1 trial

  22. A sterile preservative-free solution with identical composition as the drug product, but without the protein.

    Kiniksa Pharmaceuticals International, plc

    Sjögren’s Disease

    phase 2 small molecule active

    1 trial

  23. A study in two groups of healthy male adult participants to assess how much test medicine (SAR441566) is taken up, degraded and removed by the body and to assess the extent to which SAR441566 becomes available to the body when given by mouth

    Sanofi-aventis Healthcare Pty Ltd

    Healthy volunteers

    phase 2 other active

    1 trial

  24. A study of STX-721/PFL-721 in participants with non-small cell lung cancer with certain mutations

    Pierre Fabre Medicament

    Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 other active

    1 trial

  25. A study of niraparib in combination with abemaciclib for late line treatment of ovarian cancer: a single center, open label, single arm, phase Ib/II trial (NICHOL TRIAL)

    Fondazione Telethon ETS

    Ovarian cancer

    phase 2 other active

    1 trial

  26. A-101

    Aclaris Therapeutics

    Seborrheic Keratosis

    phase 2 small molecule completed

    2 trials

  27. A-101 25%

    Aclaris Therapeutics

    Seborrheic Keratosis (SK)

    phase 2 small molecule completed

    1 trial

  28. A-101 Solution 40

    Aclaris Therapeutics

    Common Warts

    phase 2 small molecule completed

    1 trial

  29. A-101 Topical Solution

    Aclaris Therapeutics

    Common Wart

    phase 2 small molecule completed

    2 trials

  30. A-101 Topical Solution 40%

    Aclaris Therapeutics

    Dermatosis Papulosa Nigra

    phase 2 small molecule completed

    1 trial

  31. A-101 Vehicle

    Aclaris Therapeutics

    Seborrheic Keratosis

    phase 2 small molecule completed

    1 trial

  32. A-623

    Santhera Pharmaceuticals (Deutschland) GmbH

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  33. A.1 Lucinactant

    WINDTREE THERAPEUTICS INC /DE/

    Acute Respiratory Distress Syndrome

    phase 2 small molecule terminated

    1 trial

  34. A006

    Amphastar France Pharmaceuticals

    Asthma

    phase 2 small molecule completed

    1 trial

  35. A006 DPI

    Amphastar France Pharmaceuticals

    Asthma

    phase 2 small molecule completed

    2 trials

  36. AAV2-hAADC

    PTC THERAPEUTICS, INC.

    Aromatic Amino Acid Decarboxylase Deficiency

    phase 2 small molecule completed

    1 trial

  37. AB-101

    Artiva Biotherapeutics

    Non Hodgkin Lymphoma

    phase 2 small molecule completed

    1 trial

  38. AB-201

    Artiva Biotherapeutics

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  39. AB-729

    Arbutus Biopharma Corp

    Chronic Hepatitis b

    phase 2 small molecule completed

    1 trial

  40. AB680

    Arcus Biosciences

    Metastatic Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  41. AB8939, Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets

    AB Science

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  42. ABBV-066, Lutikizumab

    AbbVie Deutschland GmbH & Co. KG

    Psoriatic Arthritis

    phase 2 small molecule active

    1 trial

  43. ABBV-066, Lutikizumab, ABBV-382, ABBV-066 / Risankizumab, ABBV-8736

    AbbVie Deutschland GmbH & Co. KG

    Moderate to Severe Crohn’s Disease

    phase 2 small molecule active

    1 trial

  44. ABBV-154

    AbbVie

    Crohn's Disease

    phase 2 small molecule terminated

    1 trial

  45. ABBV-552

    AbbVie

    Alzheimer's Disease (AD)

    phase 2 small molecule completed

    1 trial

  46. ABC294640

    RedHill Biopharma

    Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  47. ABC294640

    Apogee Therapeutics

    Diffuse Large B Cell Lymphoma

    phase 2 small molecule terminated

    1 trial

  48. ABC294640

    Apogee Therapeutics

    Carcinoma, Hepatocellular

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.